Here is a short summary from the Q2-FY18 Earnings Call Transcript of a few selected stocks. The sole objective of this post is to provide a quick short digest ...
Here is a quick summary of the 3QFY17 financial results for all the companies announced till date. For some companies, management comments have been reported ...
Effective January 9th 2017, the US Food and Drug Administration (FDA) has announced an amendment to the final rule ((the rule governs the manner in which FDA ...
Drug major Lupin has initiated a recall of Escitalopram Tablets manufactured at its Goa facility (ANDA approcal received in September, 2012) which is a generic ...
Drug major Lupin Limited has initiated a recall of 55,348 bottles of Amlodipine Besylate Tablets. This recall has been initiated for the manufacturing ...
Lupin had a good numbers in terms of sales i.e 41% growth QoQ. The net profits saw a growth of 56% QoQ. Key Takeaways: Operating Margin went up from 22.92% ...
Pharma Major Lupin Limited (Lupin) announced that its Japanese subsidiary Kyowa Pharmaceutical has entered into a strategic asset purchase agreement with ...
Drug major Lupin Pharmaceuticals Inc. (the US subsidiary of Lupin Pharmaceuticals), initiated a recall of Ceftriaxone Sodium (Sterile) vials and the API ...
